Two glycoprotein IIb-IIIa antagonists (xemilofiban, SC-54684A, and orbofiban, SC-57099B), which are platelet aggregation inhibitors, caused crystalline precipitates in the kidney tubules of rats at high dosages. Dogs were not affected. Depending on the degree of the precipitation, which was dosage dependent, and the location, which differed somewhat between the two compounds, the lesions varied from acute obstruction with tubule cell necrosis, nephron dilation, and sudden death with no inflammation to severe chronic pyogranulomatous inflammation. In order to understand the relevance of the lesions, it was important to identify the precipitates. This was technically challenging because the crystals were water soluble (dissolving in routine fixing and staining techniques) and were present in insufficient quantity to physically isolate. Techniques were devised to evaluate the crystals in situ in unstained frozen sections prepared without directly embedding the tissues in supporting medium, which interfered with the analyses. The crystals were analyzed in situ by infrared and Raman spectroscopy and time-of-flight secondary ion mass spectroscopy (TOF-SIMS). Uroliths found in the renal pelvis of one animal were analyzed by liquid chromatography/mass spectrometry. The resulting spectra showed that the crystals were the de-esterified acids of the parent compounds. This knowledge allowed us to predict that the crystalline precipitates would not be a hazard to humans because of the large multiples of the human dosage at which they occurred and because of differences in renal physiology between rats, dogs, and humans.
INTRODUCTION
The fibans are a group of compounds whose pharmacologic activity is to block the glycoprotein IIb-IIIa receptor on platelets. This receptor ordinarily binds fibrinogen, which is the final step of platelet aggregation, allowing platelets to aggregate in vivo and in vitro. The fibans reversibly block the receptor in a concentrationdependent way, causing a titratable inhibition of platelet aggregation. Unlike other antiplatelet agents, these compounds can fully block aggregation and, because they are effective when administered orally, antithrombotic treatment can be made more widely available. Two fibans under development at Monsanto/Searle are in the late stages of clinical trials: SC-54684A, known as xemilofiban, and SC-57099B, known as orbofiban. These compounds are ester prodrugs, which are absorbed after oral administration and are de-esterified to their respective pharmacologically active acids (SC-54701 for xemilofiban and SC-57101 for orbofiban). The structures of the ester prodrugs and their active acid metabolites are shown in Fig. 1 .
Platelets of humans and dogs (the animal of choice for pharmacological experiments) are highly sensitive to the effects of the fibans (for example, the 50% effective concentration [EC50] for xemilofiban is approximately 6 X 10-8 M for humans and dogs). In dog toxicity studies, the limiting toxicological findings were intramural hemorrhages in the stomach and urinary bladder and/or gingival bleeding. The fibans evaluated by Monsanto/Searle do not cause crystalline kidney lesions in dogs. Rat platelets, on the other hand, are comparatively insensitive to the fibans (EC50 for xemilofiban is approximately 3 X 10-4 M), and compound-related bleeding does not occur. The principal toxicity in the rat for both compounds, at large multiples of the human dosages, was the formation of crystalline precipitates in the kidney, leading to obstruction of urine flow, varying degrees of renal inflammation, and secondary uremia. This paper describes the kidney lesions in rats associated with these compounds and the procedures used to identify the crystalline precipitates in situ.
KIDNEY LESIONS IN THE RAT
The gross and microscopic appearance of the kidney lesions with both fiban compounds varied with the amount of the precipitates, their location within the kidney, and the length of time the animals survived after tubular obstruction (based on histological evidence of the chronicity of inflammation). Some animals that apparently succumbed peracutely after obstruction had no gross lesions or had vague changes such as pale and/or slightly swollen kidneys. Animals that survived longer had a myriad of pinpoint white spots on the kidney surface and white streaks corresponding to the obstructed tubules on the cut surface (Fig. 2 ). Some animals had little or no histological evidence of inflammation, suggesting that they succumbed quickly (more common with orbofiban). These animals usually had obstructive nephropathy characterized by dilated nephrons (Fig. 3 ) Other animals had inflammation of variable degree and duration. The earliest inflammation consisted of infiltrates of neutrophils surrounding crystals within tubules (Fig.  4 ). Various extensions of this process led ultimately to extensive chronic pyogranulomatous inflammation (Fig. 5 ) (more common with xemilofiban). Variability of the stage of inflammation within some individual animals suggested they had repeated obstructive events.
Xemilofiban-related crystalline precipitates were found with about equal frequency in all parts of the kidney (cortex, medulla, and papilla), whereas orbofiban precipitates were found predominantly in the papilla. The propensity for orbofiban to precipitate in the papilla often led to complete obstruction of urine outflow; these animals apparently died more quickly after the precipitates formed and thus tended to have relatively little inflammation. Xemilofiban often was associated with a greater amount of kidney inflammation. The randomness of the xemilofiban lesion locations, and perhaps the timing of the precipitation events, apparently permitted the animals to live longer after the insults.
An early observation with xemilofiban (the first of the 2 compounds to be in development), and later orbofiban, was the presence of what was termed &dquo;radial casts&dquo; in the lumens of kidney tubules, collecting ducts, or both at varying levels of the nephron. These radial casts were composed of eosinophilic proteinaceous material arranged in concentric rings (Fig. 6 ). The casts were present in animals whether or not they had nephritis. No birefringent material was seen in these casts, but their appearance suggested that they once may have contained crystals. We hypothesized that the putative crystals were water soluble and thus had been removed from the sections by fixation in aqueous formalin or by the routine hematoxylin and eosin staining protocol. In this scenario, the casts represented the proteins that filled the interstices of the crystals. In subsequent experiments, we fixed portions of kidneys in absolute ethanol and stained the sections with Diffouick4' for only a few seconds. These techniques minimized exposure to water and preserved the crystals, whose birefringence could then easily be observed with polarized light (Fig. 7 ). The xemilofiban crystals were sharp spikes radiating out from a central core, whereas the orbofiban crystals were more blunt.
CRYSTAL IDENTIFICATION
Infrared spectroscopy, Raman spectroscopy, time-offlight secondary ion mass spectroscopy (TOF-SIMS), and liquid chromatography/mass spectroscopy (LC/MS) were used to identify the crystals in situ. This work is briefly summarized here.
TOF-SIMS is a surface analytical technique that is well known in the physical sciences but less familiar in the biological sciences. The technique uses the impact of a primary ion beam to dislodge and eject intact molecular or fragment ions from the surface into the gas phase for time-of-flight mass analysis. TOF-SIMS combines the analytical power of mass spectrometry with the imaging ability of microprobe techniques. It allows elemental and molecular surface mapping, but only to the depth of a few angstroms. The analysis is conducted with the ion beam pulsed for a short time, on the order of picoseconds, and the time-of-flight-that is, the time taken for the ions to reach a detector-is measured between pulses. The primary ion beam is rastered over the surface, thereby producing secondary ions from various locations on the surface. Selected ion images may be produced by plotting counts from a given mass range or combination of ranges versus the coordinates from which they arose. Sections of rat kidney containing the crystals caused by xemilofiban were evaluated using TOF-SIMS. Trials showed that paraffin-embedded specimens were unsuitable for this technique because of interference from surface residues, even after dewaxing. Routinely prepared frozen sections using OCT4' embedding medium were also unsuitable for the same reason. We devised a successful technique, however, by attaching frozen kidney specimens to a cryomicrotome chuck with OCT, taking care that the top (sectioning) surface of the specimen was free of the medium. Sections made from these specimens were collected on silver-coated silicon wafers to avoid xemilofiban, its acid metabolite (SC-54701), and the crystal within the rat kidney. It is clear that the spectrum of SC-54701 and the spectrum of the renal crystal are identical, registering with the same masses as SC-54701 and its fragments. LC/MS is the direct combination of liquid chromatography with mass spectrometry through an interface that provides ionized sample to the mass spectrometer. Liquid chromatography (LC) is the most versatile and popular method for the separation of mixtures of organic compounds, and mass spectrometry is one of the most powerful structure determination methods. The interfacing of the effluent of the chromatograph to the mass spectrometer is accomplished by passing the liquid through a heated tube jacketed with a nebulizing gas to facilitate desolvation of the analyte. The resulting vapor is ionized by an electric discharge from a needle point. The ions formed at atmospheric pressure are then drawn into the high vacuum of the mass spectrometer through a -100-)JLm orifice and mass analyzed. This process is known as atmospheric pressure ionization. Electrospray ionization is a variant of this technique in which the tube through which the LC eluent passes is placed at a potential of several kilovolts with little or no heat being applied. The high voltage produces ions at atmospheric pressure that are subsequently analyzed by the mass spectrometer. Both of these techniques produce primarily protonated molecular ions, MH+, and little or no fragmentation.
Fragmentation, and thus structural information, is induced by accelerating the molecules slightly as they enter the mass spectrometer, which results in increased collisions with the surrounding gas. Careful interpretation of these data is a powerful method for structural determination and identification of unknown organic compounds.
Although LC/MS is a standard and commonly applied analytical technique, it requires the analyte to be a solution and thus is not amenable to in situ observations such as was done in tissue sections with TOF-SIMS. In 1 rat given very high doses of xemilofiban over several days, small (1-2-mm-diameter), fragile uroliths were found in the renal pelvis at necropsy. An impression smear of 1 of the uroliths showed crystalline material with the same appearance as the precipitates in the kidney tubules. The remainder of these uroliths were dissolved, and standard LC/MS performed on the solution gave the same result as TOF-SIMS, that is, that the crystalline material was SC-54701.
Infrared and Raman spectroscopy are widely used techniques for the determination of molecular structure and for the identification of compounds. Both of these methods provide information on molecular vibrations, yet differ in the means by which the photon energy is trans- ferred to the molecule. Infrared spectroscopy is an absorption-based technique whereby a broad-band source of radiation in the infrared region is used to excite a molecule to a higher vibrational state. Raman spectroscopy, on the other hand, is based on an inelastic scattering effect or emission whereby a monochromatic radiation source (laser), typically much higher in energy than infrared radiation, is used for excitation. Thus, infrared and Raman spectroscopies provide complementary information that exhibits different characteristics. With the infrared technique, a molecule is excited to a higher vibrational energy state by directly absorbing the infrared radiation. The result is an absorption spectrum that is a plot of absorbance versus wavenumbers measured per centimeter. The amount of absorbed radiation is dependent on the molecule's absorptivity, cell thickness, and concentration. With the Raman technique, a molecule is excited and then relaxes either by elastic or inelastic scattering. Most of the molecules exhibit elastic scattering, which means they relax to the original vibrational state by reemitting a photon at the same frequency as the incident light. A very small fraction of the molecules undergo inelastic scattering, whereby the excited molecule relaxes to a different vibrational level than the original state. Thus, the energy carried by this inelastically scattered light is different from that of the incident light. The energy difference between the incident light and the scattered light is depicted in a Raman spectrum and appears as a frequency shift between the scattered light and the excitation frequency.
Specimens of kidney containing crystals formed after orbofiban administration were prepared for infrared and Raman spectroscopy by sectioning frozen tissue in a cryostat using the embedding medium for attachment to the specimen holder as previously explained. The sections were collected on special sodium chloride discs (32 mm diameter X 1 mm thick) that transmit infrared light.
The sections for Raman spectroscopy were collected on ordinary glass slides but were not stained or coverslipped.
The crystalline precipitates for both methods were first identified by visible light microscopy using polarizing filters. The excitatory beams of the infrared and Raman spectrographic equipment were then narrowed to the size of the crystals being analyzed. Spectrographs were taken from the crystals themselves, from the adjacent tissue free of crystalline material, and from reference specimens of orbofiban and its active acid metabolite, When the spectra of the background tissue were mathematically subtracted from the spectra taken over the crystals, the resulting spectra were virtually identical to those of SC-57101 ( Fig. 9 ).
URINE VOLUME: A KEY BIOLOGICAL FACTOR
With both fibans, it became apparent that the no-effectlevel for the crystalline precipitation decreased with the duration of the study. This raised the question of whether the toxic effects were manifested by the duration of exposure or by physiological changes in the animals as they grew and aged. To answer this question, an experiment was conducted in which rats of various ages (6 wk, 6 mo, 12 mo, and 18 mo) were administered xemilofiban at the same dosage for 2 wk. Control groups were available for each age group. A dosage was chosen that had been shown to be nontoxic in young rats for short durations of administration (2 wk) but that had been shown to be toxic in old rats after chronic administration. This study showed conclusively that the 12and 18-mo-old rats were more susceptible than 6-wk-old or 6-mo-old rats.
Examination of the data showed that chronic progressive nephropathy (CPN) , which was increased in the older rats, did not appear to be a factor in crystalline precipitation since some of the animals most severely affected by CPN did not develop the precipitates. Glomerular filtration rate, as measured by creatinine clearance FIG. 10. -The graph of body weight and urine volume versus age of rats shows that body weight increases with age, but urine volume remains fairly constant over the age range from 6 wk to 18 mo. per 100 g of body weight, was unchanged in the older rats. The factors that appeared to have the most influence on the increased susceptibility of the older rats were body weight and urine volume. Figure 10 illustrates that body weight increased steadily as the animals aged. Urine volume, on the other hand, stays remarkably constant as the animals age and grow. Since animals are typically dosed on a milligram per kilogram of body weight basis in toxicity studies, the older (and thus larger) animals were administered larger total amounts of the fibans. Both compounds are almost entirely excreted by the kidneys. Thus, as animals grow, the increasingly larger total amount of the administered compound must be excreted in the same volume of urine. This obviously can lead to supersaturation and precipitation of the compound in the urine.
CONCLUSIONS
The acid metabolites of xemilofiban and orbofiban can precipitate in rat kidney tubules when the urine becomes supersaturated with these compounds. Since the rat is not susceptible to the inhibition of platelet aggregation by these compounds, much larger amounts of the fibans can be administered to this species than to dogs or humans. Large multiples of the human dose are required to cause the crystalline precipitates in rats. In dogs and humans, dose-limiting hemorrhage or blood loss should theoretically preclude the high plasma and urine concentrations needed to cause precipitates in the kidneys of these species.
